Send to

Choose Destination
Int J Stem Cells. 2018 Nov 30;11(2):227-234. doi: 10.15283/ijsc18053.

The Pharmacological Inhibition of ERK5 Enhances Apoptosis in Acute Myeloid Leukemia Cells.

Author information

Department of Stem Cell Biology, School of Medicine, Konkuk University, Seoul, Korea.
Stem Cell Research Center, Jeju National University, Jeju, Korea.
Mirae Cell Bio Co. LTD, Seoul, Korea.


Acute myeloid leukemia (AML) is a fatal hematological malignancy which is resistant to a variety of chemotherapy drugs. Extracellular signal-regulated kinase 5 (ERK5) plays a novel role in chemoresistance in some cancer cells and this pathway is a central mediator of cell survival and apoptotic regulation. The aim of this study was to investigate the effect of ERK5 inhibitor, XMD8-92, on proliferation and apoptosis in AML cell lines. Findings showed that XMD8-92 inhibited the activation of ERK5 by G-CSF and decreased the expression of c-Myc and Cyclin D1. The treatment of XMD8-92 reduced the phosphorylation of ERK5 leading to a distinct inhibition of cell proliferation and increased apoptosis in Kasumi-1 and HL-60 cells. Taken together, our study suggests that the inhibition of ERK5 by XMD8-92 can trigger apoptosis and inhibit proliferation in AMLs. Therefore, the inhibition of ERK5 may be an effective adjuvant in AML chemotherapy.


Acute myeloid leukemia; Apoptosis; Cell cycle; ERK5; XMD8-92

Free full text

Supplemental Content

Full text links

Icon for Inforang
Loading ...
Support Center